Sharetry Biotech Co., Ltd, a leading biotechnological company in China, develops and supplies the ZP-IgG Test, an advanced diagnostic tool to assess the fertility status of females. This innovative assay is designed to measure the levels of IgG antibodies against the zona pellucida, a glycoprotein layer surrounding the oocyte, in serum or plasma samples.
The ZP-IgG Test is a reliable and cost-effective method to diagnose infertility caused by autoimmune factors, which affects up to 25% of women seeking fertility treatment. It enables clinicians to identify patients with high anti-ZP IgG titers, who may benefit from specific therapies, such as plasmapheresis, immunoglobulin infusion, or steroid treatment, to reduce their antibody levels and improve their chances of conception.
As a manufacturer, supplier, and factory of advanced medical devices, Sharetry Biotech Co., Ltd, ensures the quality, efficacy, and safety of the ZP-IgG Test, using state-of-the-art technology and rigorous quality control standards. Our mission is to provide innovative and reliable solutions to improve the health and well-being of people worldwide.